PATENT CLAIM ANALYSIS

Application Number: 15862355
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-07
Patent Classification: ["544", "236000"]

Abstract:
Novel crystalline ponatinib hydrochloride forms designated Form alpha and Form beta are disclosed. Form alpha is characterized by data selected from an XRPD pattern with peaks at about 6.5, 9.0, 12.25, 14.4, 16.70, 19.6, 22.2, 24.5, 28.2±0.2 degrees 2-theta; an XRPD pattern substantially as depicted in FIG.  1;  and/or a combination thereof. Form beta is characterized by data selected from an XRPD pattern with peaks at about 10.7,15.2, 15.8, 16.4 23.1, 25.0, 27.8±0.2 degrees 2-theta; an XRPD pattern substantially as depicted in FIG.  3;  and/or combinations thereof. Processes for making Form alpha and Form beta are disclosed.

Claim (Index 9):
Crystalline ponatinib hydrochloride Form beta according to  claim 8 , characterized by an XRPD pattern with peaks at about 10.7, 15.2, 15.8, 16.4 23.1, 25.0, 27.8\u00b10.2 degrees 2-theta.

Metadata:
- Claim Count in Document: 32.0
- Percentile: 86.0
- Lexical Diversity: 1.98333
- Patent Class: 544.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14651577', '14902790', '15341898', '10623237', '10746697']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7382389780504647
- 35 USC 102 Novelty (BERT): 0.500014036138527
- Combined Prediction Score: 0.7144164838592709
- Mean Citation Score: 214.930728
- Max Citation Score: 240.90654
- Similarity Product: 180.5892413348508

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test